{"id":"triptorelin-acetate-pr-1-month","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Hot flashes"},{"rate":"10-20","effect":"Injection site reaction"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"10-30","effect":"Decreased libido"},{"rate":"10-25","effect":"Erectile dysfunction"},{"rate":"5-10","effect":"Gynecomastia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Triptorelin binds to GnRH receptors in the pituitary gland, initially causing a surge in gonadotropin release followed by sustained suppression of LH and FSH through receptor desensitization. This results in profound suppression of testosterone in males and estrogen in females, making it useful for hormone-dependent conditions. The 1-month formulation provides sustained release of the peptide over approximately 30 days.","oneSentence":"Triptorelin is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:12.252Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer"},{"name":"Endometriosis"},{"name":"Uterine fibroids"},{"name":"Central precocious puberty"}]},"trialDetails":[{"nctId":"NCT03232281","phase":"PHASE3","title":"Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis","status":"COMPLETED","sponsor":"Ipsen","startDate":"2017-07-28","conditions":"Endometriosis","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Diphereline 3.75 mg"],"phase":"phase_3","status":"active","brandName":"Triptorelin Acetate PR 1-month","genericName":"Triptorelin Acetate PR 1-month","companyName":"Ipsen","companyId":"ipsen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triptorelin is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production. Used for Advanced prostate cancer, Endometriosis, Uterine fibroids.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}